RobertsRJ. Drug therapy in infants, pharmacologic principles and clinical experience. Philadelphia: WB Saunders Co, 1984.
2.
DikshitK, VydenJK, ForresterJS, . Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med1973;288:1087.
3.
IkramH, ChanW, EspinerEA, NichollsMG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci1980;59:443.
4.
KaoLC, WarburtonD, ChengMH, CedenoC, PlatzkerACG, KeensTG. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: Results of a double-blind crossover sequential trial. Pediatrics1984;74:37–44.
5.
NajakZD, HarrisEM, LazzaraA, PruittAW. Pulmonary effects of furosemide in preterm infants with lung disease. J Pediatr1983;102:758–763.
PatelH, YehTF, JainR, PildesR.Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia. AJDC1985;139:917–919.
8.
McCannEM, LewisK, DemingDD, DonovanJ, BradyJP. Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr1985;106:957–962.
9.
FinbergL.Furosemide—uses, abuses, and unsolved puzzles (letter). AJDC1983;137:1145.
10.
VenkataramanPS, HanBK, TsangRC, DaughertyCC. Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy. AJDC1983;137:1157–1161.
ViscardiRM, FaixRG, NicksJJ, GraselaTH. Efficacy of theophylline for prevention of post-extubation respiratory failure in very low birthweight infants. J Pediatr1985;107:469–472.
13.
HowellJ, ClozelM, ArandaJV. Adverse effects of caffeine and theophylline in the newborn infant. Sem Perinatol1981;5:359–369.
14.
SosulskiR, AbbasiS, FoxWW. Therapeutic value of terbutaline in bronchopulmonary dysplasia (abstract). Pediatr Res1982;16:309A.
15.
RigaudM, BoschatJ, RochaP, . Comparative haemodynamic effects of dobutamine and isoproterenol in man. Intensive Care Med1977;3:57.
16.
RosenblumR, BerkowitzWD, LawsonD.Effect of acute intravenous administration of isoproterenol on cardiorenal hemodynamics in man. Circulation1968;38:158.
17.
ShettigarUR, HultgrenHN, SpecterM, . Primary pulmonary hypertension. Favorable effect of isoproterenol. N Engl J Med1976;295:1414.
18.
KaoLC, WarburtonD, PlatzkerACG, KeensTG. Effect of isoproterenol inhalation on airway resistance in chronic bronchopulmonary dysplasia. Pediatrics1984;73:509–514.
19.
MorrisHG. Mechanisms of glucocorticoid action in pulmonary disease. Chest1985;88:133S–141S.
20.
MammelMC, GreenTP, JohnsonDE, ThompsonTR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet1983;1:1356–1357.
21.
AveryGB, FletcherAB, KaplanM, BrudnoDS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics1985;75:106–111.
22.
BondWS. Toxic reactions and side effects of glucocorticoids in man. Am J Hosp Pharm1977;34:479.
MilsteinJM, GoetzmanBW, BennettSH. Pulmonary vascular response to digoxin. Am J Hosp Pharm1977;34:479. Pediatr Res 1981;15:468.
25.
SmithTW, HaberE.Digitalis (fourth of four parts). N Engl J Med1973;289:1125.
26.
WarburtonD, BellEF, OhW.Pharmacokinetics and echocardiographic effects of digoxin in low birth weight infants with left-to-right shunting due to patent ductus arteriosus. De Pharmacol Ther1980;1:189.
27.
FriedmanWF, GeorgeBL. Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr1985;106:697–706.
28.
RobertsRJ. Pulmonary oxygen toxicity in the premature and full-term infant its relationship to the development and pathogenesis of RDS and its complications. In: SternL, ed. Hyaline membrane disease. New York: Grune and Stratton Inc, 1984.
29.
HallidayHL, DumpitFM, BradyJP. Effects of inspired oxygen on echocardiographic assessment of pulmonary vascular resistance and myocardial contractility in bronchopulmonary dysplasia. Pediatrics1980;65:536–540.
30.
AbmanSH, WolfeRR, AccursoFJ, KoopsBL, BowmanM, WigginsJW. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics1985;75:80–84.
31.
DrummondWH, LockJE. Neonatal 'pulmonary vasodilator' drugs. Dev Pharmacol Ther1984;7:1–20.
32.
HymanAL, KadowitzPJ. Vasodilator therapy for pulmonary hypertensive disorders (editorial). Chest1984;85:145–147.
33.
BormanJB, MerinG, MajblumS, . The beneficial effects of chlorpromazine on pulmonary hemodynamics after cardiopulmonary bypass. Ann Thorac Surg1971;11:570.
34.
RunkleB, BancalariE.Acute cardiopulmonary effects of pancuronium bromide in mechanically ventilated newborn infants. J Pediatr1984;104:614–617.
35.
NickersonBG. Chronic pulmonary disease following neonatal respiratory failure. Chest1985;87:528–535.
36.
RobertsRJ. Implications of nutrition in oxygen-related pulmonary disease in the human premature infant. Adv Pharm Ther1978;8:53–64.
EhrenkranzRA, AblowRC, WarshawJB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann NY Acad Sci1982;393:452–458.
39.
WardJA, RobertsRJ. Vitamin E inhibition of the effects of hyperoxia on the pulmonary surfactant system of the newborn rabbit. Pediatr Res1984;18:329–334.
40.
RosenfeldW, EvansH, ConcepcionL, JhaveriR, SchaefferH, FriedmanA.Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr1984;105:781–785.
41.
EnhorningG, ShermanA, PossmayerF, DunnM, ChenCP, MilliganJ.Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: A randomized clinical trial. Pediatrics1985;76:145–153.
42.
ShapiroDL, NotterRH, MorinFC, . Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics1985;76:593–599.
43.
KwongMS, EganEA, NotterRH, ShapiroDL. Double blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics1985;76:585–592.
